novartis_rm_logo_pos_rgb.png

Redefining Fluid Control: 

Advancements in diagnosis, monitoring, and management of anatomical outcomes in wAMD and ▼Beovu (brolucizumab) Real World Data.

Wednesday 25th May 2022 | 18:30 – 20:30 BST

Agenda
Click to enter
Technical Support
Prescribing Information & Adverse Event Reporting

This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Ltd.

UK | May 2022 | 212948

​

Your attendance at the event is governed by our Healthcare Professional Event Attendance Terms. By attending the event, you are agreeing to be bound by such terms.

​

Adverse events should be reported. Reporting forms and information can be found at  www.mhra.gov.uk/yellowcard (UK).

Adverse events should also be reported to Novartis via  uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at  www.report.novartis.com

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at  medinfo.uk@novartis.com